Loren Data's SAM Daily™

fbodaily.com
Home Today's SAM Search Archives Numbered Notes CBD Archives Subscribe
SAMDAILY.US - ISSUE OF MAY 27, 2021 SAM #7117
SOLICITATION NOTICE

65 -- Acquisition of non-GMP-grade GS-441524 for the Treatment of COVID-19

Notice Date
5/25/2021 5:36:52 AM
 
Notice Type
Combined Synopsis/Solicitation
 
NAICS
325412 — Pharmaceutical Preparation Manufacturing
 
Contracting Office
NATIONAL INSTITUTES OF HEALTH NIDA Bethesda MD 20892 USA
 
ZIP Code
20892
 
Solicitation Number
75N95021Q00197
 
Response Due
5/27/2021 5:59:00 AM
 
Archive Date
05/28/2021
 
Point of Contact
Kimberly Espinosa
 
E-Mail Address
kimberly.espinosa@nih.gov
(kimberly.espinosa@nih.gov)
 
Description
THIS IS A NON-COMPETITIVE (NOTICE OF INTENT) COMBINED SYNOPSIS SOLICITATION TO AWARD A CONTRACT OR PURCHASE ORDER WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME). The National Institute on Drug Abuse (NIDA), Office of Acquisition (OA), on behalf of the National Center for Advancing Translational Sciences (NCATS), intends to negotiate and award a purchase order without providing for full and open competition (including brand-name) to Avisa Pharma Solutions, Inc. (dba Cambrex), 3501 Tricenter Blvd Ste C, Durham, NC� 27713-1868. To ensure consistency among material, the current requirement must be manufactured by the same vendor that is manufacturing the cGMP and non-GMP material under Contract No. 75N95021P00063. Therefore, this acquisition is restricted to Avisa Pharma Solutions, Inc. (dba Cambrex). (i)�������� This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in Subpart 12.6 as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; quotations are being requested and a written solicitation will not be issued. (ii)������� The solicitation number is 75N95021Q00197 and the solicitation is issued as a request for quotation (RFQ). This acquisition is for a commercial item and is conducted under the authority of the Federal Acquisition Regulation (FAR) Part 13 - Simplified Acquisition Procedures, FAR Subpart 13.5 � Simplified Procedures for Certain Commercial Items, and FAR Part 12 - Acquisition of Commercial Items, and is expected to exceed the simplified acquisition threshold. (iii)������ The solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular 2021-05, effective March 10, 2021. (iv)������ The associated NAICS code is 325412 and the Small Business size standard is 1,250 employees. This requirement is non-competitive and no set-aside restrictions are applicable. DESCRIPTION (v)������� The National Center for Advancing Translational Sciences (NCATS) is a part of the National Institutes of Health (NIH), with a mission to catalyze the generation of innovative methods and technologies that will enhance the development, testing and implementation of diagnostics and therapeutics across a wide range of human diseases and conditions. NCATS is evaluating GS-441524 as a potential treatment for SARS-CoV-2 infection. GS-441524 is the parent nucleoside of remdesivir and has similar efficacy to remdesivir in vitro. GS-441524 is a stable crystalline compound with good physical properties for formulation, and the 3-step synthesis of GS-441524 makes it suitable for large scale production. The purpose of this acquisition is to obtain 3Kg of non-GMP GS-441524. This requirement includes the following items: Line Item 1: Three (3) kg of non-GMP-grade GS-441524. This batch must be developed using the same manufacturing processes and criteria used for previous batches manufactured for this project under Contract No. 75N95021P00063, and accompanied by a Statement of Analysis (SOA). �(vi)����� The material shall be delivered within six (6) months after the date of award. �Delivery of the GS-441524 shall be made to the below city / state, FOB Destination. The exact address and point of contact will be included on the resultant award. ����������� Chicago, IL 60616 The GS-441524 shall be shipped in a manner that does not adversely affect its quality. The contractor shall ensure that the vendor transporting the GS-441524 knows and follows the appropriate transport and storage conditions. See the attached Request for Quotations (RFQ) and other attachments for complete requirement details, terms, and conditions.
 
Web Link
SAM.gov Permalink
(https://beta.sam.gov/opp/694f8583e42949448cf64f567e148f10/view)
 
Record
SN06012589-F 20210527/210525230104 (samdaily.us)
 
Source
SAM.gov Link to This Notice
(may not be valid after Archive Date)

FSG Index  |  This Issue's Index  |  Today's SAM Daily Index Page |
ECGrid: EDI VAN Interconnect ECGridOS: EDI Web Services Interconnect API Government Data Publications CBDDisk Subscribers
 Privacy Policy  Jenny in Wanderland!  © 1994-2024, Loren Data Corp.